Leila Maouche-Chretien

Dr. Leila Maouche-Chretien


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2010 in Nature
Verified
Journal Article
Closed access
PDF file
MCMarina Cavazzana
Marina Cavazzana
EPEmmanuel Payen
Emmanuel Payen
ONOlivier Negre
Olivier Negre
GWGary Wang
Gary Wang
KHKathleen Hehir
Kathleen Hehir
PLPhilippe Leboulch
Philippe Leboulch

1 January 2008 in Cell Stem Cell
Verified
Journal Article
Closed access
CLClaudia Lengerke
Claudia Lengerke
SSSabine Schmitt
Sabine Schmitt
TBTeresa V. Bowman
Teresa V. Bowman
IJIl Ho Jang
Il Ho Jang
Leila Maouche-ChretienLeila Maouche-Chretien
Leila Maouche-Chretien
GDGeorge Q. Daley
George Q. Daley

1 January 2015 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
APAnne Prel
Anne Prel
VCVincent Caval
Vincent Caval
RGRégis Gayon
Régis Gayon
PRPhilippe Ravassard
Philippe Ravassard
CDChristine Duthoit
Christine Duthoit
JPJean-Christophe Pagès
Jean-Christophe Pagès
RNA delivery is an attractive strategy to achieve transient gene expression in research projects and in cell- or gene-based therapies. Despite significant efforts investigating vector-directed RNA transfer, there is still a requirement for better efficiency of delivery to primary cells and in vivo. Retroviral platforms drive RNA delivery, yet retrovirus RNA-packaging constraints limit gene transfer to two genome-molecules per viral particle. To improve retroviral transfer, we designed a dimerization-independent MS2-driven RNA packaging system using MS2-Coat-retrovirus chimeras. The engineered chimeric particles promoted effective packaging of several types of RNAs and enabled efficient transfer of biologically active RNAs in various cell types, including human CD34(+) and iPS cells. Systemic injection of high-titer particles led to gene expression in mouse liver and transferring Cre-recombinase mRNA in muscle permitted widespread editing at the ROSA26 locus. We could further show that the VLPs were able to activate an osteoblast differentiation pathway by delivering RUNX2- or DLX5-mRNA into primary human bone-marrow mesenchymal-stem cells. Thus, the novel chimeric MS2-lentiviral particles are a versatile tool for a wide range of applications including cellular-programming or genome-editing.

1 September 2005 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
ZKZahra Kadri
Zahra Kadri
Leila Maouche-ChretienLeila Maouche-Chretien
Leila Maouche-Chretien
HRHeather M. Rooke
Heather M. Rooke
SOStuart H. Orkin
Stuart H. Orkin
PRPaul-Henri Romeo
Paul-Henri Romeo
SCStany Chretien
Stany Chretien
The contribution of erythropoietin to the differentiation of the red blood cell lineage remains elusive, and the demonstration of a molecular link between erythropoietin and the transcription of genes associated with erythroid differentiation is lacking. In erythroid cells, expression of the tissue inhibitor of matrix metalloproteinase (TIMP-1) is strictly dependent on erythropoietin. We report here that erythropoietin regulates the transcription of the TIMP-1 gene upon binding to its receptor in erythroid cells by triggering the activation of phosphatidylinositol 3-kinase (PI3K)/Akt. We found that Akt directly phosphorylates the transcription factor GATA-1 at serine 310 and that this site-specific phosphorylation is required for the transcriptional activation of the TIMP-1 promoter. This chain of events can be recapitulated in nonerythroid cells by transfection of the implicated molecular partners, resulting in the expression of the normally silent endogenous TIMP-1 gene. Conversely, TIMP-1 secretion is profoundly decreased in erythroid cells from fetal livers of transgenic knock-in mice homozygous for a GATAS310A gene, which encodes a GATA-1 mutant that cannot be phosphorylated at Ser310. Furthermore, retrovirus-mediated expression of GATAS310A into GATA-1null-derived embryonic stem cells decreases the rate of hemoglobinization by more than 50% compared to expressed wild-type GATA-1. These findings provide the first example of a chain of coupling mechanisms between the binding of erythropoietin to its receptor and GATA-1-dependent gene expression.

9 June 2009 in PLOS Biology
Verified
Journal Article
Open access
PDF file
ZKZahra Kadri
Zahra Kadri
RSRitsuko Shimizu
Ritsuko Shimizu
OOOsamu Ohneda
Osamu Ohneda
Leila Maouche-ChretienLeila Maouche-Chretien
Leila Maouche-Chretien
SGSylvie Gisselbrecht
Sylvie Gisselbrecht
SCStany Chretien
Stany Chretien
How cell proliferation subsides as cells terminally differentiate remains largely enigmatic, although this phenomenon is central to the existence of multicellular organisms. Here, we show that GATA-1, the master transcription factor of erythropoiesis, forms a tricomplex with the retinoblastoma protein (pRb) and E2F-2. This interaction requires a LXCXE motif that is evolutionary conserved among GATA-1 orthologs yet absent from the other GATA family members. GATA-1/pRb/E2F-2 complex formation stalls cell proliferation and steers erythroid precursors towards terminal differentiation. This process can be disrupted in vitro by FOG-1, which displaces pRb/E2F-2 from GATA-1. A GATA-1 mutant unable to bind pRb fails to inhibit cell proliferation and results in mouse embryonic lethality by anemia. These findings clarify the previously suspected cell-autonomous role of pRb during erythropoiesis and may provide a unifying molecular mechanism for several mouse phenotypes and human diseases associated with GATA-1 mutations. Red blood cell production, or erythropoiesis, proceeds by a tight coupling of proliferation and differentiation. The earliest erythroid progenitor identifiable possesses remnant stem cell characteristics as it both self-renews and differentiates. Each progenitor gives rise to more than 10,000 cells, including secondary progenitors. Yet, during the next stage of differentiation, much of this renewal capability is lost, and terminal erythroid differentiation progresses in a stepwise manner through several stages separated by a single mitosis. The transcription factor GATA-1 is essential for erythroid differentiation because it induces the expression of all the known erythroid-specific genes. Here, we show that GATA-1 directly interacts with proteins that are central to the process of cell division: the retinoblastoma protein pRb and the transcription factor E2F. Specifically, E2F becomes inactivate after engaging in a GATA-1/pRb/E2F tricomplex. Another erythroid transcription factor, termed FOG-1, is able to displace pRb/E2F from this complex in vitro upon binding to GATA-1. We hypothesize that the liberated pRb/E2F can then be the target of subsequent regulation to ultimately release free E2F, which triggers cell division. The physiological role of this new pathway is evidenced by transgenic mouse experiments with GATA-1 mutants unable to bind pRb/E2F, which result in embryonic lethality by anemia.

1 September 1998 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
SCSylvia Cohen-Kaminsky
Sylvia Cohen-Kaminsky
Leila Maouche-ChretienLeila Maouche-Chretien
Leila Maouche-Chretien
LVLuigi Vitelli
Luigi Vitelli
MVMarie‐Antoinette Vinit
Marie‐Antoinette Vinit
IBIsabelle Blanchard
Isabelle Blanchard
PRPaul‐Henri Roméo
Paul‐Henri Roméo
Despite the major functions of the basic helix–loop–helix transcription factor TAL‐1 in hematopoiesis and T‐cell leukemogenesis, no TAL‐1 target gene has been identified. Using immunoprecipitation of genomic fragments bound to TAL‐1 in the chromatin of murine erythro‐leukemia (MEL) cells, we found that 10% of the immunoselected fragments contained a CAGATG or a CAGGTG E‐box, followed by a GATA site. We studied one of these fragments containing two E‐boxes, CAGATG and CAGGTC, followed by a GATA motif, and showed that TAL‐1 binds to the CAGGTG E‐box with an affinity modulated by the CAGATG or the GATA site, and that the CAGGTG–GATA motif exhibits positive transcriptional activity in MEL but not in HeLa cells. This immunoselected sequence is located within an intron of a new gene co‐expressed with TAL‐1 in endothelial and erythroid cells, but not expressed in fibroblasts or adult liver where no TAL‐1 mRNA was detected. Finally, in vitro differentiation of embryonic stem cells towards the erythro/megakaryocytic pathways showed that the TAL‐1 target gene expression followed TAL‐1 and GATA‐1 expression. These results establish that TAL‐1 is likely to activate its target genes through a complex that binds an E‐box–GATA motif and define the first gene regulated by TAL‐1.